Grants / Department of Health and Human Services / Centers for Disease Control - NCEZID

CDC-RFA-CK24-2401: Emerging Infections Program

Closed Closed June 20, 2023 Opportunity CDC-RFA-CK24-2401 ☆ Save

This grant is closed. A newer notice from the same program is forecast: Continuing Enhanced National Surveillance for Prion Diseases in the United States (CDC-RFA-CK-27-0046). Status: Expected deadline March 27, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2023.

• Total funding$767 million
• Expected awards15
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to any type of organization.

The eligibility criteria below will be used to determine whether the applicant has met the program responsiveness criteria for Phase I Review. AuthorityEligible applicants must have the public health authority, legislative mandate or otherwise show legal access to the requisite data to conduct population-based infectious disease surveillance and take appropriate public health action based on the data. This authority allows unique and specific access to individual-level identifiable data from multiple data sources that are required to implement the activities outlined in this NOFO and in the individual EIP Programmatic “Approach” sections in Attachment 1 – EIP 2024 Activities. Eligible applicants must document this authority in "Other Attachment Forms" with attachment name "Legal Authority". CDC will consider any application that does not include this required documentation as non-responsive, and it will receive no further review. For eligible applicants who do not explicitly possess the public health authority or legislative mandate but are able to receive access to data (with a commitment and pathway to taking public health action) from their respective public health agency, these applicants must submit a signed letter from public health agency leadership or designee on organizational letterhead. This data access must allow for unique and specific access to individual-level identifiable data from multiple data sources that are required to implement the activities outlined in this NOFO and in the individual EIP Programmatic “Approach” sections in Attachment 1 – EIP 2024 Activities. In order to be responsive to the Phase I Review, the signed letter by the public health agency leadership or designee must also include the role(s) of the public health agency (e.g., co-lead and participate in which EIP activities throughout the five-year period of performance, etc.) and explicitly state that they agree to provide the applicant access to public health data needed for the proposed EIP activities for the catchment population of [enter catchment population for your jurisdiction] in [enter your jurisdiction] for the duration of the period of performance. Eligible applicants must document this data access in "Other Attachment Forms" with attachment name "Data Access". CDC will consider any application that does not include this required documentation as non-responsive, and it will receive no further review.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (83% over five years) went to state and local governments.
• No cost sharing or match is required.

What the grant funds

The Emerging Infections Program (EIP) was initiated in 1995 in response to the growing concern over the emergence and re-emergence of infectious diseases. Following the 1992 Institute of Medicine report "Emerging Infections: Microbial Threats to the United States,” CDC developed and published in 1994 a plan for addressing these threats. That plan highlighted the foundational role of public health surveillance and included in its recommendations, the creation of a network of population-based centers of excellence established through state public health departments collaborating with academic institutions, local health departments, public health and clinical laboratories, infection control professionals, healthcare providers, and CDC for special surveillance and applied public health research, which became the EIP network. The EIP network assists with local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. Activities of the EIP network fall into the following overall categories: (1) active infectious disease surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) rapid and flexible response to public health emergencies and newly emerging issues for infectious diseases. The EIP network is particularly suited to address key and emergent public health issues for the U.S. that require a collaborative approach across multiple sites and timely data to inform public health policy and practices and lead directly to the prevention of disease. The EIP network conducts active, population-based surveillance and special studies for respiratory viral diseases (influenza, COVID-19, RSV), invasive bacterial diseases including antibiotic-resistant infections, foodborne pathogens, healthcare-associated infections (HAIs), and many other infectious diseases. The COVID-19 pandemic has highlighted the importance of having a multi-center surveillance and applied research platform to rapidly respond to public health threats. The EIP network has also played a critical role in responding to emerging infectious diseases by rapidly implementing new collaborative activities, such as the establishment of COVID-NET to rapidly gather public health data for action on COVID-19 hospitalization rates, patient characteristics, and vaccine effectiveness.

Category: Health.

Applying now

This notice no longer takes applications. Apply under the newer notice, CDC-RFA-CK-27-0046, which is forecast.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.